LOMITAPIDE - AN OVERVIEW

The overall boost in the risk of uterine most cancers with tamoxifen use is minimal (less than 1%), and it goes again to typical inside of a couple of years of halting the drug.Tamoxifen functions like estrogen in a few tissues and blocks estrogen activity in other tissues. It binds to estrogen receptors blocking development of ER-good breast tissu